
SOL-1 data show OTX-TKI extends rescue-free control in treatment-naive wet AMD, shaping AI-driven trial design and longer-interval care.

Mark Barakat, MD, is a vitreoretinal surgeon and director of research at the Retina Macula Institute of Arizona, where he specializes in the surgical and medical management of complex retinal diseases. He is an active clinical trial investigator and a recognized voice in retinal drug development, with a focus on advancing next-generation therapies for conditions including neovascular age-related macular degeneration.

SOL-1 data show OTX-TKI extends rescue-free control in treatment-naive wet AMD, shaping AI-driven trial design and longer-interval care.

New pathways are reshaping the management of retinal disease.

Results from expert surveys provide snapshots of our understanding of DME and shed light on where the 0.19-mg FAc implant stands in the current standard of care.